Effects of β-blocker selectivity on blood pressure variability and stroke: A systematic review

Neurology

Volumn 77, Issue 8, 2011, Pages 731-737

  Webb, Alastair John Stewart ^a   Fischer, Urs ^a   Rothwell, Peter Malcolm ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; METOPROLOL; NEBIVOLOL; PLACEBO; PROPRANOLOL;

BLOOD PRESSURE VARIABILITY; CARDIOSELECTIVITY; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; BLOOD PRESSURE; FACTUAL DATABASE; RETROSPECTIVE STUDY; STATISTICS;

ADRENERGIC BETA-ANTAGONISTS; BLOOD PRESSURE; DATABASES, FACTUAL; HUMANS; HYPERTENSION; RETROSPECTIVE STUDIES; STROKE;

EID: 80054026308     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31822b007a     Document Type: Review

References (28)

1. Rothwell PM. Limitations of the usual BP hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010;375:938-948.
2. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic BP, and episodic hypertension. Lancet 2010;375:895-905.
3. Rothwell PM, Howard SC, Dolan E, et al, ASCOT-BPLA and MRC Trial investigators. Effects of βblockers and calcium-channel blockers on within-individual variability in BP and risk of stroke. Lancet Neurol 2010;9:469-480.
4. Webb AJS, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in BP and risk of stroke: a systematic review and metaanalysis. Lancet 2010;375:906-915.
5. Lindholm LH, Carlberg B, Samuelsson O. Should βblockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-1553. (Pubitemid 41540112)
6. Reiter MJ. Cardiovascular drug class specificity: β-blockers. Prog Cardiovasc Dis 2004;47:11-33. (Pubitemid 39420270)
7. The β-Blocker Pooling Project Research Group. The β-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988;9:8-16.
8. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β-Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-1737. (Pubitemid 29290470)
9. Heidenreich PA, McDonald KM, Hastie T, et al. Metaanalysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999;281: 1927-1936. (Pubitemid 29242807)
10. Fauchier L, Pierre B, deLabriolle A, Babuty D. Comparison of the beneficial effect of β-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: a meta-analysis of randomised controlled trials. Eur J Heart Fail 2007;9:1136-1139. (Pubitemid 47633317)
11. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine: report of an EFNS task force. Eur J Neurol 2006;13:560-572. (Pubitemid 43873628)
12. Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Neurology 2000;55: 754-762.
13. Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005;64:2008 -2020. (Pubitemid 40880986)
14. Stone J, Carson A, Duncan R, et al. Who is referred to neurology clinics? The diagnoses made in 3781 new patients. Clin Neurol Neurosurg 2010;112:747-751.
15. Thanvi B, Lo N, Robinson T. Essential tremor: the most common movement disorder in older people. Age Ageing 2006;35:344-349. (Pubitemid 43941801)
16. British National Formulary 60. London: BMJ Publishing and RPS Publishing; 2010.
17. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97-104.
18. The IPPPSH Collaborative Group et al. Cardiovascular risk and risk factors in a randomized trial of treatment based on the β-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertension 1985;3:379-392.
19. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.
20. The effect of pindolol on the two years mortality after complicated myocardial infarction. Eur Heart J 1983;4: 367-375.
21. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-412.
22. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009;339:b3914.
23. Alvarez Sabin J, Molins A, Turon A, Titus F, Codina A. [Migraine-infarct in patients treated with β-blockers.] Rev Clin Esp 1993;192:228-230.
24. Mendizabal JE, Greiner F, Hamilton DO, Rothrock JF. Migrainous stroke causing thalamic infarction and amnesia during treatment with propranolol. Headache 1997;37: 594-596. (Pubitemid 27508255)
25. Bardwell A, Trott JA. Stroke in migraine as a consequence of propranolol. Headache 1987;27:381-383. (Pubitemid 17152612)
26. Rothwell PM, Coull AJ, Giles MF, et al. Change in stroke incidence, mortality, case-fatality, severity and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004;363:1925-1933. (Pubitemid 38759651)
27. Rothwell PM, Giles MF, Flossman E, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet 2005;366:29-36. (Pubitemid 40956527)
28. Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008;8:35-44. (Pubitemid 351311518)